ArticleNature communications2026
Iterative discovery of potent polymeric antibiotics via multi-stage and multi-task learning against antimicrobial resistance.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Design and applications of barrier membranes for guided bone regeneration.Bioactive materials · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Drug-resistant bacterial infections pose a serious threat to global health, driving the development of antibacterial strategies beyond classic antibiotics. Host defense peptide mimetic polymeric antibiotics have emerged as promising candidates to combat drug resistance, however, navigating the vast chemical space of polymers remains a significant challenge due to complex structure-activity relationships, while data-driven approaches are further constrained by polymer complexity and scarce labeled data. To address this, we develop PolyCLOVER, a framework that integrates multi-stage self-supervised learning, active learning, and high-throughput experimentation to iteratively discover polymeric antibiotics with potent antibacterial activity and low toxicity. Applied to a combinatorial library of ~100,000 poly(β-amino ester)s, the framework uncovers three lead compounds that self-assemble into stable nanoparticles (SANPs) with minimum inhibitory concentrations of 4 μg/mL and 8 μg/mL against multidrug-resistant S. aureus and A. baumannii, respectively. These SANPs also serve as adjuvant antibiotic carriers, restoring bacterial sensitivity to penicillin G. In vivo studies demonstrate their therapeutic efficacy both as monotherapies and in combination therapies with antibiotics. PolyCLOVER may become a powerful framework for discovery of new polymeric biomaterials without reliance on external datasets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.